Echo Therapeutics (NSDQ:ECTE) priced its public stock offering at 75¢ per share, saying it expects to raise about $10 million in gross proceeds.
The 13.3 million-share offering includes a 45-day over-allotment option for bookrunner Aegis Capital for another 2 million shares.
European Union regulators are poised to give the OK to Johnson & Johnson‘s (NYSE:JNJ) $21.3 billion acquisition of Swiss orthopedic giant Synthes, according to Reuters.
Wall Street investors drove Insulet (NSDQ:PODD) shares up nearly 4% today ahead of the insulin management company’s 4th-quarter and full-year earnings statement.
Bedford, Mass.-based Insulet posted losses of $14.3 million, or 30 cents per share, on sales of $47.2 million for the 3 months ended Dec. 31, 2011, adding 70% to the top line and shaving 31.3 percent off of its losses, compared with the same period in 2010.
MassDevice Network
@MassDevice
LinkedIn
YouTube